Drug Search Results
More Filters [+]

Dexfosfoserine

Alternative Names: dexfosfoserine, phosphoserine
Latest Update: 2024-05-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: mGluR3 Agonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Argentina | Chile

Approved Indications: None

Known Adverse Events: None

Company: Hospital Universitari Vall d'Hebron Research Institute
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Dexfosfoserine

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Oxidative Stress|Chronic Pain

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ReConnect

P3

Completed

Oxidative Stress|Chronic Pain

2013-01-01

Recent News Events